Mohamed El Sayes

National Research Centre

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Mohamed A. Ali

National Research Centre

Ahmed Kandeil

St. Jude Children's Research Hospital

Rabeh El‐Shesheny

National Research Centre

Yassmin Moatasim

National Research Centre

Ghazi Kayali

Dubai Medical College

Ahmed El Taweel

National Research Centre

Mina Nabil Kamel

National Research Centre

Omnia Kutkat

National Research Centre

Mokhtar R. Gomaa

National Research Centre

Richard J. Webby

St. Jude Children's Research Hospital

Cooperative Institutions

University of KwaZulu-Natal

128

Stellenbosch University

104

Africa Centres for Disease Control and Prevention

Kenya Medical Research Institute

Redeemer's University

Institut Pasteur

University of Ghana

Cairo University

Inserm

Mohammed V University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Potent Antiviral Activity of Vitamin B12 against Severe Acute Respiratory Syndrome Coronavirus 2, Middle East Respiratory Syndrome Coronavirus, and Human Coronavirus 229E

Microorganisms (2023)

Yassmin Moatasim Omnia Kutkat Ahmed M. Osman Mokhtar R. Gomaa Faten A. Okda

Repurposing vitamins as antiviral supporting agents is a rapid approach used to control emerging viral infections. Although there is considerable evidence supporting the use of vitamin supplementation in viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the specific role of each vitamin in defending against coronaviruses remains unclear. Antiviral activities of available vitamins on the infectivity and replication of human coronaviruses, namely, SARS-CoV-2, Middle East respiratory syndrome coronavirus (MERS-CoV), and human coronavirus 229E (HCoV-229E), were investigated using in silico and in vitro studies. We identified potential broad-spectrum inhibitor effects of Hydroxocobalamin and Methylcobalamin against the three tested CoVs. Cyanocobalamin could selectively affect SARS-CoV-2 but not MERS-CoV and HCoV-229E. Methylcobalamin showed significantly higher inhibition values on SARS-CoV-2 compared with Hydroxocobalamin and Cyanocobalamin, while Hydroxocobalamin showed the highest potent antiviral activity against MERS-CoV and Cyanocobalamin against HCoV-229E. Furthermore, in silico studies were performed for these promising vitamins to investigate their interaction with SARS-CoV-2, MERS-CoV, and HCoV-229E viral-specific cell receptors (ACE2, DPP4, and hAPN protein, respectively) and viral proteins (S-RBD, 3CL pro, RdRp), suggesting that Hydroxocobalamin, Methylcobalamin, and Cyanocobalamin may have significant binding affinity to these proteins. These results show that Methylcobalamin may have potential benefits for coronavirus-infected patients.

Coronavirus

Hydroxocobalamin

Methylcobalamin

Nidovirales

Common cold

Coronaviridae

10.3390/microorganisms11112777

Cite

Citations (4)

Coding-Complete Genome Sequences of Two SARS-CoV-2 Isolates from Egypt

Microbiology Resource Announcements (2020)

Ahmed Kandeil Ahmed Mostafa Rabeh El‐Shesheny Mahmoud Shehata Wael H. Roshdy

This report announces the complete genome sequences of two severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolates detected in Egypt. The isolates were obtained from oropharyngeal swab specimens from two Egyptians in Upper and Lower Egypt. Sequence analysis showed mutations that differentiate Egyptian strains from the reference strain 2019-nCoV WHU01.

Strain (injury)

Coronavirus

Coding region

10.1128/mra.00489-20

Cite

Citations (60)

In Vitro and In Vivo Antiviral Studies of New Heteroannulated 1,2,3-Triazole Glycosides Targeting the Neuraminidase of Influenza A Viruses

Pharmaceuticals (2022)

Omnia Kutkat Ahmed Kandeil Yassmin Moatasim Yaseen A. M. M. Elshaier Wael A. El‐Sayed

There is an urgent need to develop and synthesize new anti-influenza drugs with activity against different strains, resistance to mutations, and suitability for various populations. Herein, we tested in vitro and in vivo the antiviral activity of new 1,2,3-triazole glycosides incorporating benzimidazole, benzooxazole, or benzotriazole cores synthesized by using a click approach. The Cu-catalyzation strategy consisted of 1,3-dipolar cycloaddition of the azidoalkyl derivative of the respective heterocyclic and different glycosyl acetylenes with five or six carbon sugar moieties. The antiviral activity of the synthesized glycosides against wild-type and neuraminidase inhibitor resistant strains of the avian influenza H5N1 and human influenza H1N1 viruses was high in vitro and in mice. Structure-activity relationship studies showed that varying the glycosyl moiety in the synthesized glycosides enhanced antiviral activity. The compound (2R,3R,4S,5R)-2-((1-(Benzo[d]thiazol-2-ylmethyl)-1H-1,2,3-triazol-4-yl)methoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (Compound 9c) had a 50% inhibitory concentration (IC50) = 2.280 µM and a ligand lipophilic efficiency (LLE) of 6.84. The compound (2R,3R,4S,5R)-2-((1-((1H-Benzo[d]imidazol-2-yl)methyl)-1H-1,2,3-triazol-4-yl)methoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate had IC50 = 2.75 µM and LLE = 7.3 after docking analysis with the H5N1 virus neuraminidase. Compound 9c achieved full protection from H1N1 infection and 80% protection from H5N1 in addition to a high binding energy with neuraminidase and was safe in vitro and in vivo. This compound is suitable for further clinical studies as a new neuraminidase inhibitor.

Zanamivir

1,2,3-Triazole

Triazole

Oseltamivir

10.3390/ph15030351

Cite

Citations (18)

Common childhood vaccines do not elicit a cross-reactive antibody response against SARS-CoV-2

PLoS ONE (2020)

Ahmed Kandeil Mokhtar R. Gomaa Ahmed El Taweel Ahmed Mostafa Mahmoud Shehata

Anecdotal evidence showed a negative correlation between Bacille Calmette-Guérin (BCG) vaccination and incidence of COVID-19. Incidence of the disease in children is much lower than in adults. It is hypothesized that BCG and other childhood vaccinations may provide some protection against SARS-CoV-2 infection through trained or adaptive immune responses. Here, we tested whether BCG, Pneumococcal, Rotavirus, Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenzae, Hepatitis B, Meningococcal, Measles, Mumps, and Rubella vaccines provide cross-reactive neutralizing antibodies against SARS-CoV-2 in BALB/c mice. Results indicated that none of these vaccines provided antibodies capable of neutralizing SARS-CoV-2 up to seven weeks post vaccination. We conclude that if such vaccines have any role in COVID-19 immunity, this role is not antibody-mediated.

10.1371/journal.pone.0241471

Cite

Citations (15)

Genetic and virological characteristics of a reassortant avian influenza A H6N1 virus isolated from wild birds at a live-bird market in Egypt

Archives of Virology (2024)

Omnia Kutkat Mokhtar R. Gomaa Basma Emad Aboulhoda Yassmin Moatasim Ahmed El Taweel

Medical microbiology

10.1007/s00705-024-06022-6

Cite

Citations (0)

Molecular identification and virological characteristics of highly pathogenic avian influenza A/H5N5 virus in wild birds in Egypt

Microbial Pathogenesis (2022)

Ahmed Kandeil Ahmed E. Kayed Yassmin Moatasim Basma Emad Aboulhoda Ahmed N. El Taweel

Reassortment

Highly pathogenic

H5N1 genetic structure

Hemagglutination assay

10.1016/j.micpath.2022.105928

Cite

Citations (5)

Improving Fault Ride-Through Capability of Fixed-Speed Wind Turbine Using Combined Shunt and Series Compensation Scheme

Bulletin of the Faculty of Engineering Mansoura University (2020)

Mohamed El Sayes M. El-Said Mohamed Eskander

This paper proposes a fault ride-through (FRT) scheme with alternatively employing shunt and series compensation for enhancing FRT capability of the fixed speed wind turbine (FSWT).A combined approach based on shunt and series grid interface topology for one voltage source converter (VSC) is used to enhance FRT capability for the FSWT.The VSC in its shunt interface topology works as a static synchronous compensator (STATCOM) to regulate voltage in normal operation and in light voltage dip.In case of serious grid voltage dip the VSC instantaneously switches from shunt to series grid interface and works as static synchronous series compensator (SSSC) injecting a series voltage through series coupling transformer to compensate the terminal voltage of the wind turbine generator (WTG).The proposed control scheme, utilizing positive and negative sequence controllers, provides a transient management solution for both balanced and unbalanced fault conditions.A comprehensive simulation study using PSCAD/EMTDC simulation program demonstrate the performance of the proposed scheme for enhancing the FRT

10.21608/bfemu.2020.98786

Cite

Citations (0)

FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2

Pharmaceuticals (2020)

Ahmed Mostafa Ahmed Kandeil Yaseen A. M. M. Elshaier Omnia Kutkat Yassmin Moatasim

(1) Background: Drug repositioning is an unconventional drug discovery approach to explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue to alleviate the COVID-19 pandemic disease. (2) Methods: Herein, we tested the antiviral activity of anti-microbial and anti-inflammatory Food and Drug Administration (FDA)-approved drugs, commonly prescribed to relieve respiratory symptoms, against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the viral causative agent of the COVID-19 pandemic. (3) Results: Of these FDA-approved antimicrobial drugs, Azithromycin, Niclosamide, and Nitazoxanide showed a promising ability to hinder the replication of a SARS-CoV-2 isolate, with IC50 of 0.32, 0.16, and 1.29 µM, respectively. We provided evidence that several antihistamine and anti-inflammatory drugs could partially reduce SARS-CoV-2 replication in vitro. Furthermore, this study showed that Azithromycin can selectively impair SARS-CoV-2 replication, but not the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). A virtual screening study illustrated that Azithromycin, Niclosamide, and Nitazoxanide bind to the main protease of SARS-CoV-2 (Protein data bank (PDB) ID: 6lu7) in binding mode similar to the reported co-crystalized ligand. Also, Niclosamide displayed hydrogen bond (HB) interaction with the key peptide moiety GLN: 493A of the spike glycoprotein active site. (4) Conclusions: The results suggest that Piroxicam should be prescribed in combination with Azithromycin for COVID-19 patients.

Nitazoxanide

Drug repositioning

Coronavirus

Niclosamide

10.3390/ph13120443

Cite

Citations (153)

Correction: El-Shesheny et al. Highly Pathogenic Avian Influenza A(H5N1) Virus Clade 2.3.4.4b in Wild Birds and Live Bird Markets, Egypt. Pathogens 2023, 12, 36

Pathogens (2024)

Rabeh El‐Shesheny Yassmin Moatasim Sara H. Mahmoud Yi Song Ahmed El Taweel

Text Correction [...]

Highly pathogenic

Bird flu

10.3390/pathogens13090726

Cite

Citations (0)

Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors

Frontiers in Microbiology (2020)

Mokhtar R. Gomaa Ahmed Kandeil Ahmed Mostafa Wael H. Roshdy Ahmed E. Kayed

Using convalescent plasma as immunotherapy is an old method for treatment of infectious diseases. Several countries have recently allowed the use of such therapy for the treatment of COVID-19 patients especially those who are critically ill. A similar program is currently being tested in Egypt. Here, we tested 227 plasma samples from convalescent donors in Egypt for neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using a microneutralization (MN) assay. A third of the tested samples did not have antibody titers and 58% had titers between 1:10 and 1:80. Only 12% had titers >1:160. We also compared MN assays using different virus concentrations, plaque reduction neutralization (PRNT) assays, and a chemiluminescence assay that measures immunoglobulin G (IgG) binding to N and S proteins of SARS-CoV-2. Our results indicated that a MN assay using 100 TCID50/ml provides comparable results to PRNT and allows for high throughput testing.

Convalescent plasma

Coronavirus

10.3389/fmicb.2020.596851

Cite

Citations (6)